V on Willebrand disease( VWD) type 2c omprises the qualitative defects of VWFm olecule (1).Among them, VWD2Nisthe result of mutations in the D' or D3 domains in the N-terminal region that cause VWFwith adefective binding capacity to FVIII,resulting in the prematuredegradation of FVIII (2).
Heterozygousi ndividuals areg enerally asymptomatic,b ut homozygotes and compound heterozygotes have phenotypes mimicking hemophilia A(3). The presenceofconfounding genetic factors, suchasthose conferredbyVWD type 1, would explain the variability in phenotype.
Thirty-nine mutations( exons 18-21 and 24) in VWD2 N were reported to the vonWillebrand diseasedatabaseofthe International Society on Thrombosis and Haemostasis (4).Inaddition, amutation in exon 25 causing defective binding and multimerization has beendescribed recently(5-8).
The R924Q substitution, encoded within exon 21 of VWF gene,was described as apolymorphism.Using site-directed mutagenesis and transient expression in COS-7 cells,Hilbert et al. (9) showed thatR 924Q substitution wasapolymorphism because the VWF:FVIIIBo ft he mutated recombinant VWFw as similar to thatofwild type recombinantVWF.However,the patient displayed moderatelydecreased VWF:FVIIIB,VWF and FVIII levels. Thea uthors consideredt he symptoms related to other novelmutations, Q1053H and C1060R.
We report the R924Qsubstitution in twomembersofafamily and in an unrelated man, with mildlyreduced VWF:FVIIIB and ableeding tendency.
Case reports
The proband (P1) wasa48-year-old man with apreviousdiagnosis of sporadichemophilia A. He suffered from epistaxis, hematomas, bleeding after tooth extraction, and major hemorrhages related to surgical procedures thatrequired treatment with FVIII concentrates.Hepresentedseveral episodesofhemarthrosis, all post-traumatic. The first,atthe age of 10 years,was in the knee. Other joint bleedingswere tarsusin1999, leftwrist and scapuloclavicular in 2002. In addition, he suffered from acephalohematoma in 2002. All episodesrequired FVIII concentrates.The response to desmopressin infusion wasinadequate because FVIII did not reachh emostatic levels after the infusiono ft he drug (Table 1) . His 24-year-old son (P2) sufferedfrom bleeding after tooth extraction thatrequired FVIII concentrates.His daughter (P3, 26-year-old) suffered fromeasybruising butnootherbleeding symptoms; she hada nu neventful pregnancya nd delivery. His granddaughter(P4, 2-year-old,daughter of P3) hadnohemorrhagic episodes.
Anon-related 61-year-old man (P5) with gingivalb leeding and severe epistaxisduring childhood that requirednasal packing wasevaluatedaswell. His familyhistorywas notsignificant, except forhis brotherwho had epistaxis butcould not be studied.
One hundrede ighty-three unrelated blood donors (366 alleles) were controls.
Bloodsamples VWF:Ag wasassayedb yenzyme-linked immunosorbent assay (10); FVIII activity wasmeasured by one-stage method (11),and VWF:RCow as determinedb ya na ggregometer method (12) . FVIII binding to immobilized VWF wasperformed by an ELISA method (13) . Multimericanalysis wasassayedbyimmunoenzymatic stain usinga vidin-biotin peroxidase complex (14) . The evaluation wasperformed applying scanning densitometryusing Heteroduplex analysis and Conformation-Sensitive Gel Electrophoresis( CSGE)w ere performed as previously described (15, 16) . Amplified DNAfragmentswere purified with the use of aGFX kit(Amersham PharmaciaBiotech).Sequence analysis of amplifiedD NA fragmentsw as performed with the use of aDYEnamic ET Terminator Cycle Sequencing Kit (AmershamB iosciences). Automateds equencing of PCR fragments wasperformed on an ABIPrism 310Genetic Analyzer (Applied Biosystems).
All samples were screened by CSGE and sequenced.
Results
Table2summarizes the phenotypic data.P1, P2 yP5showeda decreasedFVIII/VWF:Ag.P1and P2 presentedmildlyreduced VWF:F VIIIB,w hile P5 had an ormal binding capacity.T he threeofthem were heterozygousfor the substitution R924Q encodedwithin exon 21 of the VWFgene. P3 and P4 were homozygousf or R924. No other mutations were detected by CSGE screening or in the DNAsequencing studies. Clinicalpenetrance in this familywas 100% because allthe carriers of the mutation were symptomatic.
R924Q substitutionw as notf ound in the 366 allelesf rom normal controls. Multimericpattern wasnormal both in patients and in normal controls.
Discussion
Our observations suggest thatR924Q might have implications in phenotypic expression of VWDb ecausew eh avef ound the R924Q mutation in symptomatic patients butn ot in asymptomatic familymembersnor in the generalpopulation. Moreover, the European Study Molecular and Clinical Markers fort he Diagnosis and Management of Ty pe 1VWD (MCMDM-1VWD) reportedt hat missense mutations predominated in the study population, among them R924Q wasfound in four patients with ac linical penetrance of 78%( 17, 18), similar to our patients. However, the contribution of the mutation to the phenotype deserves further investigation.
Becausemutations in exons 17 and 18 change the consensus sequence for the specific Furin/PACE enzyme abolishingt he cleavage of VWF pro-peptide leading to adecreased capacity of VWFtobind FVIII in plasma (8, 19), we extendedour sequencing strategy to include exon 17 butd etected no changes there. However, even though unlikely, we cannot excludeany other alteration located outside exons 17-24 that mayaffect the VWF: FVIIIB and the bleeding tendency.
Someauthors have proposedthat the genotype would determine the response or the lack of responset od esmopressin in these patients (20) (21) (22) (23) .Our patient did not achieve an adequate response to DDAV P, because FVIII levels did not reach hemostatic values. However, we cannot excludenor assess the role of R924Q in the response to DDAV P.
In summary,bleeding tendency, adecreased FVIII/VWF:Ag and R924Q substitutionw ere concomitantlyp resenti nt wo members of this familya nd in an unrelated man, all of them symptomatic, butn ot in the generalp opulation or in asymptomatic familymembers. However, furtherreportsare required to showthe role of R924Q both in phenotype and in the response to desmopressin. 
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